Moderna Japan Announces Appointment of New Representative Director and President

Moderna, Inc. (hereinafter "Moderna") today announced that Kei Kaneda, General Manager of Moderna Japan Co., Ltd. (Minato-ku, Tokyo; hereinafter "Moderna Japan"), Moderna's Japanese subsidiary, has been appointed Representative Director and President, effective April 1, 2026.

Effective April 1, 2026, Ms. Kaneda will assume the role of Representative Director and President, and as General Manager, she will be responsible for overseeing and managing the entire business operations of Moderna Japan. Moderna will continue its efforts to deliver the value of mRNA medicines, contributing to the health of the people of Japan, in close collaboration with various stakeholders, including health authorities.

Patrick Bergstedt, who previously served as Representative Director of Moderna Japan, will retire from this position effective April 1, 2026, and will continue to serve Moderna as Senior Vice President and General Manager, Asia & Emerging Markets.

About Moderna

Moderna is an innovative leader in the field of mRNA medicines. Through the advancement of mRNA technology, Moderna continues to fundamentally change how medicines are made and transform the approach to treating and preventing diseases. Since its inception, Moderna's mRNA platform has enabled the development of vaccines and therapeutics in a wide range of areas, including infectious diseases, cancer, and rare diseases.

Employees worldwide, sharing a unique corporate culture, values, and mindset, work together to contribute to people's health and strive to make the maximum impact on people through mRNA medicines. For more information about Moderna, please visit modernatx.com. Also, follow us on X, Facebook, Instagram, YouTube, and LinkedIn.

＜Contact for this matter＞

Moderna Japan Co., Ltd. Communications & Media

E-mail: [email protected]